Advertisement

Annals of Hematology

, Volume 88, Issue 8, pp 753–760 | Cite as

Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells

  • Li Jia
  • Wei Wei
  • Jun Cao
  • Henggui Xu
  • Xiaoyan Miao
  • Jianing ZhangEmail author
Original Article

Abstract

Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN or CD147), a member glycoprotein enriched on the surface of many malignant tumor cells, promotes tumor progression and confers resistance to some chemotherapeutic drugs. To investigate the possible role of CD147 in the macrophage-like lymphoid neoplasm P388D1 cells progression, we used RNA interference approach to silence CD147 expression. The results showed that silencing of CD147 in P388D1 cells impeded the expression of MMP11 at both mRNA and protein levels. The reduced CD147 expression also resulted in reductions in tumorigenicity, as well as decreased in regional lymph node metastasis. Furthermore, the down-regulation of CD147 expression sensitized cells to be more sensitive to chemotherapeutic drugs. Treatment of tumor cells with U-0126, an inhibitor of mitogen-activated protein kinase/Erk, also down-regulated the expression of MMP11. Our current results indicate that the expression of CD147 functionally mediates tumor progression and is a potential target for therapeutic anti-cancer drugs.

Keywords

CD147 RNA interference P388D1 cells Tumor progression 

Notes

Acknowledgment

This work was supported by grants from National Natural Science Foundation of China (30670466).

References

  1. 1.
    Gabison EE, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J et al (2005) EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87:361–368 doi: 10.1016/j.biochi.2004.09.023 PubMedCrossRefGoogle Scholar
  2. 2.
    Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J et al (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158:1921–1928PubMedGoogle Scholar
  3. 3.
    Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S et al (2004) Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10:3422–3428 doi: 10.1158/1078-0432.CCR-03-0610 PubMedCrossRefGoogle Scholar
  4. 4.
    Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M et al (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 10:7335–7346 doi: 10.1158/1078-0432.CCR-04-0183 PubMedCrossRefGoogle Scholar
  5. 5.
    Misra S, Ghatak S, Zoltan-Jones A, Toole BP (2003) Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278:25285–25288 doi: 10.1074/jbc.C300173200 PubMedCrossRefGoogle Scholar
  6. 6.
    Zou W, Zhu H, Wu X (2006) Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 248:211–218 doi: 10.1016/j.canlet.2006.07.005 PubMedCrossRefGoogle Scholar
  7. 7.
    Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S et al (2002) EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 19:697–702 doi: 10.1023/A:1021350718226 PubMedCrossRefGoogle Scholar
  8. 8.
    Li R, Huang L, Guo H, Toole BP (2001) Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol 186:371–379 doi: 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8 PubMedCrossRefGoogle Scholar
  9. 9.
    Sun J, Hemler ME (2001) Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61:2276–2281PubMedGoogle Scholar
  10. 10.
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMedGoogle Scholar
  11. 11.
    Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR et al (2005) MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4:293–302 doi: 10.1158/1541-7786.MCR-06-0003 CrossRefGoogle Scholar
  12. 12.
    Davidson B, Givant-Horwitz V, Laranovici P, Risberg B, Nesland JM, Trope CG et al (2002) Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis 20:621–631 doi: 10.1023/A:1027347932543 CrossRefGoogle Scholar
  13. 13.
    Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B et al (1998) Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett 441:88–92 doi: 10.1016/S0014-5793(98)01474-4 PubMedCrossRefGoogle Scholar
  14. 14.
    Khunkeawla P, Moonsom S, Staffler G, Kongtawelert P, Kasinrer KW (2001) Engagement of CD147 molecule-induced cell aggregation through the activation of protein kinases and reorganization of the cytoskeleton. Immunobiology 203:659–669PubMedGoogle Scholar
  15. 15.
    Jia L, Wang S, Cao J, Zhou H, Wei W, Zhang J (2007) siRNA targeted against matrix metalloproteinase 11 inhibits the metastatic capability of murine Hepatocarcinoma cell Hca-F to lymph nodes. IJBCB 39:2049–2062Google Scholar
  16. 16.
    Kanekura T, Chen X, Kanzaki T (2002) Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99:520–528 doi: 10.1002/ijc.10390 PubMedCrossRefGoogle Scholar
  17. 17.
    Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199PubMedGoogle Scholar
  18. 18.
    Delebecq TJ, Porte H, Zerimech F, Copin MC, Gouyer V, Dacquembronne E et al (2000) Overexpression level of stromelysin 3 is related to the lymph node involvement in nonsmall cell lung cancer. Clin Cancer Res 6:1086–1092PubMedGoogle Scholar
  19. 19.
    Deng H, Guo RF, Li WM, Zhao M, Lu YY (2005) Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. BBRC 14:274–281Google Scholar
  20. 20.
    Jia L, Cao J, Wei W, Wang S, Zuo Y, Zhang J (2007) CD147 depletion down-regulates matrix metalloproteinase-11, vascular endothelial growth factor-A expression and the lymphatic metastasis potential of murine Hepatocarcinoma Hca-F. IJBCB 39:2135–2142Google Scholar
  21. 21.
    Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O et al (2002) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20:387–392 doi: 10.1038/nbt0402-387 PubMedCrossRefGoogle Scholar
  22. 22.
    Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM et al (2007) Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 98:1064–1069 doi: 10.1111/j.1349-7006.2007.00487.x PubMedCrossRefGoogle Scholar
  23. 23.
    Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN (2003) Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1:420–427PubMedGoogle Scholar
  24. 24.
    Yang JM, Vassil AD, Hait WN (2001) Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60:674–680PubMedGoogle Scholar
  25. 25.
    Huang C, Jacobson K, Schaller MD (2004) MAP kinases and cell mobility. J Cell Sci 117:4619–4628 doi: 10.1242/jcs.01481 PubMedCrossRefGoogle Scholar
  26. 26.
    Brauchle M, Gluck D, Padova FD, Han JH, Gram H (2000) Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1. Exp Cell Res 258:135–144 doi: 10.1006/excr.2000.4913 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Li Jia
    • 1
    • 2
  • Wei Wei
    • 2
  • Jun Cao
    • 3
  • Henggui Xu
    • 2
  • Xiaoyan Miao
    • 2
  • Jianing Zhang
    • 1
    Email author
  1. 1.Department of Biochemistry, Institute of GlycobiologyDalian Medical UniversityDalianChina
  2. 2.College of Laboratory MedicineDalian Medical UniversityDalianChina
  3. 3.Department of ToxicologyDalian Medical UniversityDalianChina

Personalised recommendations